Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01109238 | A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma | completed | — | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01355679 | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma | completed | N/A | 16 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01483820 |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma |
| terminated |
| Phase 1 / Phase 2 |
| 8 |
| Giselle ShollerOTHER |
| 1 |
| Aug 6, 2024 |
| clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01802567 | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | completed | N/A | 52 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | completed | Phase 2 | 140 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT06502210 | Identification of New Gene Spliceosomes in Neuroblastoma | unknown | — | 20 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05245123 | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families(PsyRareCare) | completed | — | 100 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT03517280 | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil | completed | — | 17 | Columbia UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT02641314 | Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma(METRO-NB2012) | completed | Phase 2 | 18 | University of CologneOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02169609 | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | completed | Phase 2 | 24 | Fundació Sant Joan de DéuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT02559804 | Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)(NB-SCI) | recruiting | — | 150 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT06190574 | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma | completed | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02765243 | Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma(4SCAR-GD2) | completed | Phase 1 | 12 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03686566 | Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] | completed | — | 84 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT01505569 | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | completed | N/A | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT01526603 | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | completed | N/A | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06275334 | Dinutuximab Beta at the HUS and the Toulouse Oncopole(DNB) | unknown | — | 40 | University Hospital, Strasbourg, FranceOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | terminated | Phase 2 / Phase 3 | 52 | Y-mAbs TherapeuticsINDUSTRY | 4 | Feb 13, 2024 | clinicaltrials |
| NCT06255210 | Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)(ESICON) | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04253015 | A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta | recruiting | — | 125 | RECORDATI GROUPINDUSTRY | 7 | Feb 7, 2024 | clinicaltrials |
| NCT01661400 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors(ASCR) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04474678 | Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") | completed | N/A | 240 | Medical University of ViennaOTHER | 4 | Jan 9, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | terminated | Phase 1 | 177 | Y-mAbs TherapeuticsINDUSTRY | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02864563 | Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification(PHRCNB07) | completed | N/A | 560 | Institut CurieOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | recruiting | Phase 3 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00899990 | Collecting and Storing Biological Samples From Patients With Ewing Sarcoma | completed | — | 908 | Children's Oncology GroupNETWORK | 6 | Oct 3, 2023 | clinicaltrials |
| NCT03406273 | Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma | withdrawn | N/A | 0 | Giselle ShollerOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT01586767 | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy | unknown | N/A | 45 | Massachusetts General HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2024source: clinicaltrials